Mo, I think you forgot about OCAT -- another Cox pick that was destroyed by Mako. His attack article was very similar to the CTIX article -- empty offices, it's a scam, etc. OCAT had some great clinical trial results for their stem cell therapy -- ONE WEEK after the second Mako article saying they were going bankrupt. However, OCAT had toxic financing, and they quickly sold the company for far less than it was worth, to avoid bankruptcy or taking on even more toxic financing. Anyone who bought when Cox recommended it, and held through all the trauma over several years, lost lots of money.

AMBS was another one. Again, they were a victim of naked shorting (proven -- it was being shorted on a German exchange that they continually asked to be de-listed from) -- and also took on toxic financing. They're not dead yet but I see very little chance for that one.

So, thus far, IPIX has been Cox's only good pick. Perhaps BTX or one of the others on your list will pan out -- hope so.